Search Results - "Afzali, Ali Maisam"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Aquaporin-4 prevents exaggerated astrocytosis and structural damage in retinal inflammation by Maisam Afzali, Ali, Stüve, Lasse, Pfaller, Monika, Aly, Lilian, Steiger, Katja, Knier, Benjamin, Korn, Thomas

    “…Aquaporin-4 (AQP4) is the molecular target of the immune response in neuromyelitis optica (NMO) that leads to severe structural damage in the central nervous…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock? by Afzali, Ali, Ruck, Tobias, Wiendl, Heinz, Meuth, Sven G

    Published in Autoimmunity reviews (01-05-2017)
    “…Abstract Idiopathic inflammatory myopathies (IIMs) encompass a heterogenic group of rare muscle diseases with common symptoms including muscle weakness and the…”
    Get full text
    Journal Article
  4. 4

    Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis by Noll, Christina, Hiltensperger, Michael, Aly, Lilian, Wicklein, Rebecca, Afzali, Ali Maisam, Mardin, Christian, Gasperi, Christiane, Berthele, Achim, Hemmer, Bernhard, Korn, Thomas, Knier, Benjamin

    Published in Frontiers in immunology (11-11-2022)
    “…Background Optical coherence tomography angiography (OCT-A) is a novel technique allowing non-invasive assessment of the retinal vasculature. During relapsing…”
    Get full text
    Journal Article
  5. 5

    Skeletal muscle cells actively shape (auto)immune responses by Afzali, Ali Maisam, Müntefering, Thomas, Wiendl, Heinz, Meuth, Sven G., Ruck, Tobias

    Published in Autoimmunity reviews (01-05-2018)
    “…Histopathological analyses of muscle specimens from myositis patients indicate that skeletal muscle cells play an active role in the interaction with immune…”
    Get full text
    Journal Article
  6. 6

    Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjögren’s syndrome by Wolf, Elisabeth, Wicklein, Rebecca, Aly, Lilian, Schmaderer, Christoph, Afzali, Ali Maisam, Mardin, Christian, Korn, Thomas, Hemmer, Bernhard, Hofauer, Benedikt, Knier, Benjamin

    Published in Journal of neurology (01-07-2024)
    “…Background While retinal vessel changes are evident in the eyes of patients with relapsing–remitting multiple sclerosis (RRMS), changes in the vasculature of…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies by Ruck, Tobias, Bittner, Stefan, Afzali, Ali Maisam, Göbel, Kerstin, Glumm, Sarah, Kraft, Peter, Sommer, Claudia, Kleinschnitz, Christoph, Preuße, Corinna, Stenzel, Werner, Wiendl, Heinz, Meuth, Sven G

    Published in Oncotarget (22-12-2015)
    “…NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation by Bittner, Stefan, Ruck, Tobias, Göbel, Kerstin, Henschel, Christian, Afzali, Ali Maisam, Göb, Eva, Müntefering, Thomas, Kleinschnitz, Christoph, Wiendl, Heinz, Meuth, Sven G

    Published in The American journal of pathology (01-07-2014)
    “…Glatiramer acetate (GA) (Copaxone), a well-established drug for the treatment of multiple sclerosis, is believed to modulate numerous pathways including…”
    Get full text
    Journal Article
  13. 13

    ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential by Ruck, Tobias, Afzali, Ali Maisam, Lukat, Karl-Friedrich, Eveslage, Maria, Gross, Catharina C, Pfeuffer, Steffen, Bittner, Stefan, Klotz, Luisa, Melzer, Nico, Wiendl, Heinz, Meuth, Sven G

    Published in BMC neurology (10-03-2016)
    “…Alemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In previous phase II and III clinical trials,…”
    Get full text
    Journal Article
  14. 14